307 related articles for article (PubMed ID: 28362562)
1. Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.
Casali PG; Zalcberg J; Le Cesne A; Reichardt P; Blay JY; Lindner LH; Judson IR; Schöffski P; Leyvraz S; Italiano A; Grünwald V; Pousa AL; Kotasek D; Sleijfer S; Kerst JM; Rutkowski P; Fumagalli E; Hogendoorn P; Litière S; Marreaud S; van der Graaf W; Gronchi A; Verweij J;
J Clin Oncol; 2017 May; 35(15):1713-1720. PubMed ID: 28362562
[TBL] [Abstract][Full Text] [Related]
2. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.
Casali PG; Le Cesne A; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Adenis A; Hartmann JT; Duffaud F; Goldstein D; Broto JM; Gronchi A; Dei Tos AP; Marréaud S; van der Graaf WT; Zalcberg JR; Litière S; Blay JY
J Clin Oncol; 2015 Dec; 33(36):4276-83. PubMed ID: 26573069
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
[TBL] [Abstract][Full Text] [Related]
4. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
Heinrich MC; Rankin C; Blanke CD; Demetri GD; Borden EC; Ryan CW; von Mehren M; Blackstein ME; Priebat DA; Tap WD; Maki RG; Corless CL; Fletcher JA; Owzar K; Crowley JJ; Benjamin RS; Baker LH
JAMA Oncol; 2017 Jul; 3(7):944-952. PubMed ID: 28196207
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
Serrano C; García-Del-Muro X; Valverde C; Sebio A; Durán J; Manzano A; Pajares I; Hindi N; Landolfi S; Jiménez L; Rubió-Casadevall J; Estival A; Lavernia J; Safont MJ; Pericay C; Díaz-Beveridge R; Martínez-Marín V; Vicente-Baz D; Vivancos A; Hernández-Losa J; Arribas J; Carles J
Oncologist; 2019 May; 24(5):680-687. PubMed ID: 30126859
[TBL] [Abstract][Full Text] [Related]
6. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
[TBL] [Abstract][Full Text] [Related]
8. S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.
Blanke CD; Rankin C; Corless C; Eary JF; Mulder K; Okuno SH; George S; Heinrich M
Oncologist; 2015 Dec; 20(12):1353-4. PubMed ID: 26576593
[TBL] [Abstract][Full Text] [Related]
9. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
Blanke CD; Demetri GD; von Mehren M; Heinrich MC; Eisenberg B; Fletcher JA; Corless CL; Fletcher CD; Roberts PJ; Heinz D; Wehre E; Nikolova Z; Joensuu H
J Clin Oncol; 2008 Feb; 26(4):620-5. PubMed ID: 18235121
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
Joensuu H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Ramadori G; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Nilsson B; Sihto H; Bono P; Kallio R; Junnila J; Alvegård T; Reichardt P
J Clin Oncol; 2016 Jan; 34(3):244-50. PubMed ID: 26527782
[TBL] [Abstract][Full Text] [Related]
11. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.
Van Glabbeke M; Verweij J; Casali PG; Le Cesne A; Hohenberger P; Ray-Coquard I; Schlemmer M; van Oosterom AT; Goldstein D; Sciot R; Hogendoorn PC; Brown M; Bertulli R; Judson IR
J Clin Oncol; 2005 Aug; 23(24):5795-804. PubMed ID: 16110036
[TBL] [Abstract][Full Text] [Related]
12. Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?
Milhem M; Deutsch JM
Curr Clin Pharmacol; 2015; 10(4):311-20. PubMed ID: 26548908
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).
Rutkowski P; Nowecki ZI; Debiec-Rychter M; Grzesiakowska U; Michej W; Woźniak A; Siedlecki JA; Limon J; vel Dobosz AJ; Kakol M; Osuch C; Ruka W
J Cancer Res Clin Oncol; 2007 Sep; 133(9):589-97. PubMed ID: 17458563
[TBL] [Abstract][Full Text] [Related]
14. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)
Casali PG; Le Cesne A; Velasco AP; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Penel N; Hartmann JT; Duffaud F; Goldstein D; Martin-Broto J; Gronchi A; Wardelmann E; Marréaud S; Zalcberg JR; Litière S; Blay JY
Ann Oncol; 2021 Apr; 32(4):533-541. PubMed ID: 33482247
[TBL] [Abstract][Full Text] [Related]
15. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
Blay JY; Le Cesne A; Ray-Coquard I; Bui B; Duffaud F; Delbaldo C; Adenis A; Viens P; Rios M; Bompas E; Cupissol D; Guillemet C; Kerbrat P; Fayette J; Chabaud S; Berthaud P; Perol D
J Clin Oncol; 2007 Mar; 25(9):1107-13. PubMed ID: 17369574
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
17. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS).
Rubió-Casadevall J; Martinez-Trufero J; Garcia-Albeniz X; Calabuig S; Lopez-Pousa A; Del Muro JG; Fra J; Redondo A; Lainez N; Poveda A; Valverde C; De Juan A; Sevilla I; Casado A; Andres R; Cruz J; Martin-Broto J; Maurel J;
Ann Surg Oncol; 2015 Sep; 22(9):2948-57. PubMed ID: 25608769
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour.
Yang W; Li K; Yu J; Shou C; Zhang Q; Hong Y; Sun J; Yu H; Gao Y; Shen Q; Zhao Z; Zheng S
Scand J Gastroenterol; 2018; 53(10-11):1328-1334. PubMed ID: 30346846
[TBL] [Abstract][Full Text] [Related]
19. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors after imatinib secondary resistance: survival analysis in patients with unresectable and metastatic gastrointestinal stromal tumors.
Kanda T; Ishikawa T; Kosugi SI; Ueki K; Naito T; Wakai T; Hirota S
Int J Clin Oncol; 2016 Apr; 21(2):295-301. PubMed ID: 26386705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
